The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop

被引:240
|
作者
Lu, Xiongbin [1 ]
Ma, Ou
Nguyen, Thuy-Ai
Joness, Stephen N.
Oren, Moshe
Donehower, Lawrence A.
机构
[1] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[2] Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[4] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA
[5] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA
[6] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
基金
美国国家卫生研究院;
关键词
D O I
10.1016/j.ccr.2007.08.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor suppressor p53 is a transcription factor that responds to cellular stresses by initiating cell cycle arrest or apoptosis. One transcriptional target of p53 is Mdm2, an E3 ubiquitin ligase that interacts with p53 to promote its proteasomal degradation in a negative feedback regulatory loop. Here we show that the wild-type p53-induced phosphatase 1 (Wipl), or PPM1 D, downregulates p53 protein levels by stabilizing Mdm2 and facilitating its access to p53. Wipl interacts with and dephosphorylates Mdm2 at serine 395, a site phosphorylated by the ATM kinase. Dephosphorylated Mdm2 has increased stability and affinity for p53, facilitating p53 ubiquitination and degradation. Thus, Wipl acts as a gatekeeper in the Mdm2-p53 regulatory loop by stabilizing Mdm2 and promoting Mdm2-mediated proteolysis of p53.
引用
收藏
页码:342 / 354
页数:13
相关论文
共 50 条
  • [41] Explaining oscillations and variability in the p53-Mdm2 system
    Proctor, Carole J.
    Gray, Douglas A.
    BMC SYSTEMS BIOLOGY, 2008, 2
  • [42] In silico criterion for prediction of effects of p53 gene missense mutations on p53-Mdm2 feedback loop
    Veljkovic, Nevena
    Perovic, Vladimir
    PROTEIN AND PEPTIDE LETTERS, 2006, 13 (08): : 807 - 814
  • [43] Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner
    Esfandiari, Arman
    Curtin, Nicola J.
    Lunec, John
    CANCER RESEARCH, 2015, 75
  • [44] Molecular simulation of the p53-MDM2 binding interface
    Pantelopulos, George A.
    Voelz, Vincent A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [45] A dynamic p53-mdm2 model with distributed delay
    Horhat, Raluca
    Horhat, Raul Florin
    10TH INTERNATIONAL CONFERENCE ON MATHEMATICAL PROBLEMS IN ENGINEERING, AEROSPACE AND SCIENCES (ICNPAA 2014), 2014, 1637 : 413 - 421
  • [46] Comparative study of the p53-mdm2 and p53-MDMX interfaces
    Böttger, V
    Böttger, A
    Garcia-Echeverria, C
    Ramos, YFM
    van der Eb, AJ
    Jochemsen, AG
    Lane, DP
    ONCOGENE, 1999, 18 (01) : 189 - 199
  • [47] A dynamic P53-MDM2 model with time delay
    Mihalas, Gh. I.
    Neamtu, M.
    Opris, D.
    Horhat, R. F.
    CHAOS SOLITONS & FRACTALS, 2006, 30 (04) : 936 - 945
  • [48] Targeting the p53-MDM2 interaction to treat cancer
    Klein, C
    Vassilev, LT
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1415 - 1419
  • [49] Artificial Macrocycles as Potent p53-MDM2 Inhibitors
    Estrada-Ortiz, Natalia
    Neochoritis, Constantinos G.
    Twarda-Clapa, Aleksandra
    Musielak, Bogdan
    Holak, Tad A.
    Domling, Alexander
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (10): : 1025 - 1030
  • [50] The p53-MDM2/MDMX axis - A chemotype perspective
    Khoury, Kareem
    Popowicz, Grzegorz M.
    Holak, Tad A.
    Doemling, Alexander
    MEDCHEMCOMM, 2011, 2 (04) : 246 - 260